Abstract 29P
Background
The E3 ligase HUWE1 is a key regulator of the DNA damage response, transcription, autophagy, apoptosis and metabolism in a variety of cancers. Due to its pivotal role in conferring substrate specificity, HUWE1 has attracted enormous attention as a promising anticancer drug target. In this study, we have studied the role of HUWE1 in triple-negative breast cancer (TNBC) cell lines and evaluated its role on aerobic glycolysis which is upregulated in cancer cells and immune modulatory markers for their roles in immunotherapy. TNBC subtype neither express hormone receptors nor Her2/neu. TNBC are highly aggressive, with poor prognosis and no well-defined treatment regimen. Therefore, considering HUWE1 as an oncogene its role has been explored on glucose metabolism and immune modulation in TNBC cell lines.
Methods
Two TNBC cell lines i.e., MDA-MB-231 and MDA-MB-468 were used in the present study. These cell lines were treated with HUWE1 inhibitor: BI8622 for 24 h and the effect of inhibition was seen on its substrate (c-myc), aerobic glycolytic (HK-2, GLUT-1) and immune checkpoint markers (PDL-1, CD-47) using western blotting approach. Wound healing assays and clonogenic assays were also performed in BI8622 treated cells to check the effects of HUWE1 inhibition on migration and colony forming ability of TNBC cells in both the cell lines.
Results
As expected, there was a decrease in the protein expression levels of c-myc after the HUWE1 inhibition. Furthermore, there was decrease in protein expression of glycolytic markers i.e. HK-2 and GLUT-1 as well as immuno modulatory markers i.e. PDL-1 and CD-47. Additionally, the HUWE1 inhibition in TNBC cells was positively associated with the inhibition of migration and clonogenic potential.
Conclusions
In this study for the first time, we have demonstrated that HUWE1 acts as a tumor suppressor in TNBC by regulating the glucose metabolism and immune checkpoint inhibitors. HUWE1 inhibition could functionally suppress TNBC development possibly by regulating aerobic glycolysis and immune checkpoints through c-myc.
Clinical trial identification
Editorial acknowledgement
Funded by Indian Council of Medical Research (ICMR), New Delhi, India.
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical research (ICMR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract